Relief Therapeutics Holding AG (RLF) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.115x

Based on the latest financial reports, Relief Therapeutics Holding AG (RLF) has a cash flow conversion efficiency ratio of -0.115x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-3.76 Million ≈ $-4.75 Million USD) by net assets (CHF32.63 Million ≈ $41.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Relief Therapeutics Holding AG - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Relief Therapeutics Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Relief Therapeutics Holding AG (RLF) total liabilities for a breakdown of total debt and financial obligations.

Relief Therapeutics Holding AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Relief Therapeutics Holding AG ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Eurospan Holdings Bhd KLSE:7094	-0.377x
Midland Exploration Inc V:MD	-0.011x
Intercure TA:INCR	0.014x
Vext Science Inc F:VV5	0.059x
Dacome International Ltd TWO:9960	0.041x
Urbanise.com Ltd AU:UBN	0.336x
Milux Corporation Bhd KLSE:7935	0.023x
Biohit Oyj B HE:BIOBV	0.040x

Annual Cash Flow Conversion Efficiency for Relief Therapeutics Holding AG (2006–2024)

The table below shows the annual cash flow conversion efficiency of Relief Therapeutics Holding AG from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see RLF market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF36.66 Million ≈ $46.35 Million	CHF-2.92 Million ≈ $-3.69 Million	-0.080x	+76.41%
2023-12-31	CHF52.23 Million ≈ $66.03 Million	CHF-17.61 Million ≈ $-22.27 Million	-0.337x	-103.40%
2022-12-31	CHF145.42 Million ≈ $183.85 Million	CHF-24.11 Million ≈ $-30.48 Million	-0.166x	+15.73%
2021-12-31	CHF181.53 Million ≈ $229.50 Million	CHF-35.71 Million ≈ $-45.15 Million	-0.197x	+27.67%
2020-12-31	CHF67.04 Million ≈ $84.76 Million	CHF-18.23 Million ≈ $-23.05 Million	-0.272x	-419.88%
2019-12-31	CHF14.30 Million ≈ $18.08 Million	CHF-748.00K ≈ $-945.67K	-0.052x	-80.17%
2018-12-31	CHF21.28 Million ≈ $26.91 Million	CHF-618.00K ≈ $-781.32K	-0.029x	+48.15%
2017-12-31	CHF20.95 Million ≈ $26.48 Million	CHF-1.17 Million ≈ $-1.48 Million	-0.056x	+56.88%
2016-12-31	CHF22.24 Million ≈ $28.11 Million	CHF-2.89 Million ≈ $-3.65 Million	-0.130x	+65.57%
2015-12-31	CHF17.66 Million ≈ $22.32 Million	CHF-6.66 Million ≈ $-8.42 Million	-0.377x	-13.81%
2014-12-31	CHF26.35 Million ≈ $33.31 Million	CHF-8.73 Million ≈ $-11.04 Million	-0.331x	+22.01%
2013-12-31	CHF20.61 Million ≈ $26.06 Million	CHF-8.76 Million ≈ $-11.08 Million	-0.425x	-124.58%
2012-12-31	CHF-2.69 Million ≈ $-3.40 Million	CHF-4.65 Million ≈ $-5.87 Million	1.729x	+107.83%
2011-12-31	CHF464.04K ≈ $586.67K	CHF-10.24 Million ≈ $-12.95 Million	-22.075x	-6931.42%
2010-12-31	CHF52.38 Million ≈ $66.22 Million	CHF-16.44 Million ≈ $-20.79 Million	-0.314x	-437.12%
2009-12-31	CHF56.73 Million ≈ $71.73 Million	CHF-3.32 Million ≈ $-4.19 Million	-0.058x	+57.83%
2008-12-31	CHF68.94 Million ≈ $87.15 Million	CHF-9.55 Million ≈ $-12.08 Million	-0.139x	-139.60%
2007-12-31	CHF64.50 Million ≈ $81.54 Million	CHF-3.73 Million ≈ $-4.72 Million	-0.058x	-267.47%
2006-12-31	CHF66.13 Million ≈ $83.61 Million	CHF2.28 Million ≈ $2.89 Million	0.035x	--

About Relief Therapeutics Holding AG

SW:RLF Switzerland Biotechnology

Market Cap

$45.93 Million

CHF36.33 Million CHF

Market Cap Rank

#23049 Global

#203 in Switzerland

Share Price

CHF2.89

Change (1 day)

+0.87%

52-Week Range

CHF2.11 - CHF3.66

All Time High

CHF280.00